EUCTR2004-001430-16-IT进行中（未招募）不适用
An Open-Label, Randomized, Phase 3 Trial of Intravenous Temsirolimus (CCI-779) at Two Dose Levels Compared to Investigator's Choice Therapy in Relapsed, Refractory Subjects with Mantle Cell Lymphoma (MCL)
WYETH LEDERLE0 个研究点目标入组 177 人开始时间: 2005年12月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 177
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphoma (MCL)Mantle Cell LymphomaEUCTR2004-001430-16-ESWyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development177
进行中（未招募）
不适用
An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphoma (MCL)Mantle Cell LymphomaEUCTR2004-001430-16-SEWyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development177
进行中（未招募）
不适用
An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphoma (MCL)Mantle Cell LymphomaEUCTR2004-001430-16-ATWyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development177
进行中（未招募）
不适用
An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphoma (MCL)Mantle Cell LymphomaEUCTR2004-001430-16-DEWyeth Research, Division of Wyeth Pharmaceuticals, Inc. (A Pfizer Company)177
进行中（未招募）
不适用
An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphoma (MCL)Mantle Cell LymphomaEUCTR2004-001430-16-GBWyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development177